D. Campany Herrero, J.M. Guiu Segura, E. Vallvé Alcón, I. Cardona Pacual, J. Monterde Junyent
{"title":"Non-specific immunoglobulin titres against cytomegalovirus: An alternative to hyperimmune presentation","authors":"D. Campany Herrero, J.M. Guiu Segura, E. Vallvé Alcón, I. Cardona Pacual, J. Monterde Junyent","doi":"10.1016/S2173-5085(11)70004-1","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>Specific immunoglobulin against cytomegalovirus has demonstrated its effectiveness in preventing and treating infections in solid organ transplantation. Several studies indicate that non-specific immunoglobulin is just as effective.</p><p>This study aims to determine anti-cytomegalovirus immunoglobulin titres from one of the non-specific immunoglobulin presentations authorised in Spain.</p></div><div><h3>Method</h3><p>This was an observational study, in which we analysed the anti-cytomegalovirus antibody titres from different batches of Flebogamma<sup>®</sup> 5% 5g used at the Hospital Universitari Vall d’Hebron during 2008 and 2009.</p></div><div><h3>Results</h3><p>We analysed 27 batches, which included 18,944 vials of Flebogamma<sup>®</sup> 5%. Depending on the origin, the median concentration of anti-cytomegalovirus immunoglobulin was 28 PEI-U/ml and 22 PEI-U/ml per vial of North American and Spanish origin, respectively (CI 95% for the difference of the medians 5 to 6 PEI-U/ml; P<.001).</p></div><div><h3>Conclusions</h3><p>The anti-cytomegalovirus antibody concentration of the non-specific immunoglobulin batches analysed was slightly lower than in the specific immunoglobulin preparations. These differences can be compensated by adjusting the dosage.</p></div>","PeriodicalId":100521,"journal":{"name":"Farmacia Hospitalaria (English Edition)","volume":"35 1","pages":"Pages 23-27"},"PeriodicalIF":0.0000,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S2173-5085(11)70004-1","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Farmacia Hospitalaria (English Edition)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2173508511700041","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
Specific immunoglobulin against cytomegalovirus has demonstrated its effectiveness in preventing and treating infections in solid organ transplantation. Several studies indicate that non-specific immunoglobulin is just as effective.
This study aims to determine anti-cytomegalovirus immunoglobulin titres from one of the non-specific immunoglobulin presentations authorised in Spain.
Method
This was an observational study, in which we analysed the anti-cytomegalovirus antibody titres from different batches of Flebogamma® 5% 5g used at the Hospital Universitari Vall d’Hebron during 2008 and 2009.
Results
We analysed 27 batches, which included 18,944 vials of Flebogamma® 5%. Depending on the origin, the median concentration of anti-cytomegalovirus immunoglobulin was 28 PEI-U/ml and 22 PEI-U/ml per vial of North American and Spanish origin, respectively (CI 95% for the difference of the medians 5 to 6 PEI-U/ml; P<.001).
Conclusions
The anti-cytomegalovirus antibody concentration of the non-specific immunoglobulin batches analysed was slightly lower than in the specific immunoglobulin preparations. These differences can be compensated by adjusting the dosage.